SUNY DOWNSTATE MEDICAL CENTER

UNIVERSITY HOSPITAL OF BROOKLYN POLICY AND PROCEDURE

Subject: <u>USES AND DISCLOSURES FOR</u>

RESEARCH PURPOSES

Prepared by: Shoshana Milstein

Reviewed by: John Allen

HIPAA Oversight Committee

Approved by: Anny Yeung, RN, MPA

Margaret Jackson, MA, RN

David Conley, MBA

Stanley Fisher, M.D.

Michael Lucchesi, M.D.

Debra D. Carey, MS

Ivan M. Lisnitzer

No. HIPAA-28

Page 1 of 8

Original Issue Date 12/02

Supersedes: 12/02

Effective Date: 12/07

The JC Standards:

Issued by: Regulatory Affairs

I. PURPOSE

To ensure that all uses and disclosures of protected health information (PHI) for research purposes complies with the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its accompanying regulations.

II. POLICY

In addition to the requirements delineated in this policy, all research activities must also comply with other applicable policies addressing the requirements of the Common Rule, FDA, provision of healthcare and special categories of information (ie, genetic tests, HIV, alcohol and substance abuse, psychotherapy notes and mental health information).

III. DEFINITION(s)

None

IV. RESPONSIBILITIES

It is the responsibility of all medical staff members and hospital staff members to comply with this policy. Medical staff members include physicians as well as allied health professionals. Hospital staff members include all employees, medical or other students, trainees, residents, interns, volunteers, consultants, contractors and subcontractors at the hospital.

The development of the procedure section is the responsibility of the respective department. It is dependent upon the unique needs of each department's operating structure and shall be advanced and customized accordingly.

V. PROCEDURE/GUIDELINES

- **A. Research Not Requiring Subject Authorization-** Under the following circumstances, uses and disclosures for research purposes are permitted without the subject's authorization.
- 1. Reviews Preparatory to Research- The use and disclosure of PHI is permitted to develop a research protocol or for similar purposes preparatory to research (Ex: To determine whether there is participant information that would meet the study eligibility criteria).
 - a. The Principal Investigator (PI) must represent that (See attached Researcher Certification for Reviews Preparatory to Research):
 - i. The use or disclosure is sought solely to prepare a research protocol or for similar purposes preparatory to research;
 - ii. No researcher will remove the PHI from SUNY Downstate premises in the course of the review; and
 - iii. The PHI for which use or disclosure is sought is necessary for the research purpose.
 - b. During the preparatory review, those granted access may only record information in a de-identified format. See policy on De-identification of Information.
 - c. Once the PI has determined to go forward with the study, the continued use or disclosure of PHI is not permitted without an authorization.

2. Research on Decedent's Information

- a. The PI must represent that (See attached Researcher Certification for PHI of Decedents):
 - i. The use or disclosure is sought solely for research on the PHI of decedents; and
 - ii. The PHI for which use or disclosure is sought is necessary for the research purpose.
- b. The PI must provide documentation, at the request of the Research Foundation, of the death of any subject about whom information is sought.
- 3. IRB/ Privacy Board Approval of Waiver- Uses and disclosures of PHI for research purposes are permitted if the IRB/ Privacy Board grants a partial or total waiver of the authorization requirement. If only a partial waiver has been granted, the use or disclosure must be conditioned upon compliance with any authorization requirements that were not waived.

- a. Membership Composition- The IRB/ Privacy Board members must separately consider their roles as privacy guardian under HIPAA and overall welfare guardian under other laws and IRB policies.
 - Members must have various backgrounds and appropriate professional competency to review the effect of the protocol on the subject's privacy rights and related interests;
 - ii. The Board must include one member who is not affiliated with SUNY Downstate, any entity conducting or sponsoring the research and not related to any person affiliated with these entities or with SUNY Downstate.
 - iii. The Board cannot have any members with a conflict of interest.
- b. Waiver Criteria- The IRB/ Privacy Board should keep minutes of its meetings documenting that the requested waiver satisfies each of the following criteria:
 - i. The use or disclosure involves no more than a minimal risk to the privacy of the subjects because:
 - There is an adequate plan to protect the "identifiers" from improper use or disclosure (See policy on De-Identification of Information for the types of information considered to be "identifiers");
 - There is an adequate plan to destroy the "identifiers" at the earliest opportunity, unless there is a health or research justification for retaining the "identifiers" or their retention is required by law; and
 - There are adequate written assurances that the PHI will not be reused or disclosed to any other person or entity, except as required by law, for authorized oversight of the research study or for other research for which the use or disclosure of PHI is otherwise permitted under this policy.
 - ii. The research could not practicably be conducted without the waiver-Research involving treatment will almost never be eligible since most clinical trials could practicably be conducted without a waiver; and
 - iii. The research could not practicably be conducted without access to and use of the PHI- If de-identified information or a limited data set can practicably be used, a waiver of authorization should not be granted.
- c. Review Procedures- The IRB/ Privacy Board must follow the Common Rule's normal or expedited review procedures, as applicable.
 - i. The proposed research must be reviewed at convened meetings at which a majority of the members are present, including at least one member meeting the criteria of Section III.A.3.a.ii.
 - ii. The waiver must be approved by the majority of the members present at the meeting; and
 - iii. If it is elected to use an expedited review, the research may not involve no more than a minimal risk to the privacy of the relevant subjects. The review and approval of the waiver may be carried out by the chair or one of the chair's designated board members.
- d. Documentation of Waiver- The documentation must include a:
 - i. Statement identifying the IRB/ Privacy Board:
 - ii. Date on which the waiver was approved;
 - iii. Statement that the IRB/ Privacy Board has determined that the waiver satisfies the required criteria;

- iv. Brief description of the PHI that the IRB/ Privacy Board has determined is necessary for research purposes;
- v. Statement that the waiver has been reviewed and approved under either normal or expedited review procedures and that all applicable procedures were followed; and
- vi. Signature of the IRB/ Privacy Board chair or other member, as designated by the chair.
- 4. De-Identified Information- De-identified information that complies with the policy on De-identification of Information may be used or disclosed for research purposes without restriction.
- 5. Limited Data Sets- Uses and disclosures for research purposes of a limited data set including partially de-identified information is permitted, without an authorization, if it complies with the policy on Uses of Limited Data Sets.
- **B. Research Requiring Subject Authorization-** For all other uses and disclosures for research purposes, the PI must ensure that an authorization from the subject is obtained. See attached Instructions How to Write an Authorization Form and Sample Research Authorization Form.
- 1. For the specific requirements of an authorization form, see policy on Uses & Disclosures Requiring Patient Authorization.
- 2. The subject's ability to receive research-related treatment as part of the research study may be conditioned upon the subject's agreement to sign the authorization form; however, failure to sign cannot limit access to treatment available outside of the study.
- 3. An authorization for the use and disclosure of PHI for research may be combined with a consent to participate in the research study or with any other legal permission related to the study.
- 4. The PI must submit the authorization form to the Research Foundation for its approval before any PHI is obtained and before protocols are submitted.
- 5. Subjects may revoke the authorization at any time; however, the PHI that was obtained may continue to be used, as necessary, to maintain the integrity of the research study (Ex: To report adverse events, conduct investigations of scientific misconduct).
- **C. Special Categories of Information-** Additional guidelines are delineated in the policies on Alcohol and Substance Abuse Information, HIV- Related Information and Mental Health Information. This information pertains only to uses and disclosures for research purposes. Information that is completely de-identified or meets the requirements of a limited data set, in accordance with their respective policies, would not require the restrictions specified below.
- 1. Genetic Information
 - a. For genetic testing of human biological samples for which a research authorization is obtained, the subject must also sign a specific consent form for genetic testing under NY Civil Rights Law §79-1(2)(b). Otherwise, testing is only permissible if either:

- The tissue sample is anonymous, the research protocol has been approved by an IRB and the research protocol assures the anonymity of the sample sources; or
- ii. The subject has signed a general consent form for the use of the sample for research purposes under NY Civil Rights Law §79-1(9)(a), the sample is either permanently stripped of identifying information or is coded in accordance with an IRB-approved coding methodology and the research protocol has been approved by an IRB.
- b. The disclosure of information about a subject derived from genetic tests performed in stored human tissue or linking a subject with specific results of genetic tests to an organization or person (including sponsors and researchers) is permitted if the subject signed either a valid research authorization form or a Consent to Release Genetic Information form under NY Civil Rights Law §§79-1(3)(a) and 79-1(9)(d).

2. HIV-Related Information

- a. Definition of HIV-related Information
 - i. Information that is in the possession of a person who provides health or social services or who obtains the information pursuant to a release of confidential HIV-related information and concerns whether an individual has been the subject of an HIV-related test, has an HIV infection, HIV-related illness or AIDS; or
 - ii. Information that identifies or reasonably could identify an individual as having one or more of such conditions, including information pertaining to such person's contacts.
- b. Disclosure of HIV- related information is permitted without an authorization if the disclosure is permitted pursuant to Section III.A. of this policy and the disclosure is either to a(n):
 - i. Health facility or healthcare provider in relation to the procurement or use of a human body or body part, including organs, tissues, blood, semen or other body fluids, for use in research; or
 - ii. Employee or agent of SUNY Downstate, if:
 - The employee/ agent is permitted to access medical records;
 - SUNY Downstate is authorized by law to obtain the HIV-related information; and
 - The employee/ agent either provides healthcare to the protected individual or maintains or processes medical records for billing or reimbursement.
- c. Researchers should make every effort to obtain a NY Release of Confidential HIV-Related Information form from the subject upon first contact with the subject.
- 3. Alcohol and Substance Abuse- These restrictions apply to all alcohol and substance abuse treatment information maintained by SUNY Downstate and its clinics. They do not apply to any numbers assigned to a patient by a treatment program as long as the numbers cannot be used to identify a patient with reasonable accuracy and speed from sources external to the treatment program.
 - a. When obtaining a research authorization from the patient, a PHSA consent must be obtained, as well.
 - b. Disclosure of alcohol and substance abuse information without an authorization is permitted if the disclosure is permitted under Section III.A. of

this policy and the director of the treatment program determines that the recipient of the patient information:

- i. Is qualified to conduct research;
- ii. Has a research protocol under which the patient information will be maintained in a secure room, locked file cabinet, safe or other similar container when not in use:
- iii. Has a research protocol under which the patient information will not be re-disclosed to other than SUNY Downstate and under which patient information will not be revealed in any report generated by the researcher; and
- iv. Has provided a satisfactory written statement that a group of three or more individuals, independent of the research project, reviewed the protocol and determined that the rights and welfare of patients will be adequately protected and the risks of disclosing patient information are outweighed by the potential benefits of the research.
- c. The researcher may only re-disclose such information back to the treatment program and may not identify any individual patient in reports or disclosures.

4. Mental Health Information

- a. Definition of Mental Health Information- Clinical records or clinical information tending to identify patients who are receiving or have received mental health treatment or care.
- b. Mental health information may be released pursuant to a valid research authorization.
- c. Mental health information may be released without a valid research authorization only if the release is permitted pursuant to Section III.A. of this policy and:
 - i. The Mental Health Director (ie. Director of the ward, floor or clinic providing mental health services and would be the individual who currently has oversight of the mental health services) consents to the release; and
 - ii. The release is to qualified researchers requiring mental health information for a particular research project who have obtained appropriate approval from an IRB or from another committee specially constituted for the approval of research projects at SUNY Downstate involving mental health information.
- d. All disclosures of mental health information for research purposes must be limited to the minimum necessary for the research purpose.
- e. The researcher may not re-disclose mental health information to research sponsors, contract research organizations or any other person or organization without the prior approval of the Research Foundation.
- **D. Disclosures to DOH-** Disclosures to the Department of Health for scientific studies and research is permitted under the following circumstances, as long as the minimum necessary standards are met (See policy on Minimum Necessary Guidelines):
- 1. The subject authorizes the disclosure.
- 2. An IRB/ Privacy Board waives the authorization.
- **E. Subject Access-** Subjects generally have a right to access all their PHI maintained by SUNY Downstate or its business associate. Subjects' access rights may be

temporarily suspended while a clinical trial is in progress, provided that the subject agreed to this denial when consenting to participate in the clinical trial. Subjects requesting access should be referred to the Health Information Management Department, in accordance with the policy on Patient Requests for Access.

F. Accounting of Disclosures

- All disclosures for research purposes must be documented as delineated in the policy on Accounting of Disclosures. The following disclosures are exempted from this requirement:
 - a. Disclosures made pursuant to the subject's authorization;
 - b. Disclosures made pursuant to the policy on De-Identification of Information; and
 - c. Disclosures made pursuant to the policy on Use of Limited Data Sets.
- 2. Research disclosures- For research activities that received a waiver of patient authorization and involve 50 or more individuals, an abbreviated accounting can be provided. The researcher should coordinate the provision of this accounting with the Health Information Management Department:
 - a. The name of the protocol or other research activity;
 - b. A description of the research protocol/ activity, including the purpose of the research and the criteria for selecting particular records;
 - c. A brief description of the type of PHI that was disclosed;
 - d. The date or period of time during which disclosures occurred or may have occurred, including the date of the last such disclosure during the accounting period;
 - e. The name, address and telephone number of the entity that sponsored the research and of the researcher to whom the information was disclosed;
 - f. A statement that the PHI of the patient may or may not have been disclosed for a particular research protocol/ activity.
- **H. Documentation-** All documentation required by this policy must be maintained for a period of six (6) years from the date of its creation or the date last in effect, whichever is later.

VI. ATTACHMENTS

Researcher Certification for Reviews Preparatory to Research, Researcher Certification for PHI of Decedents, HIPAA Waiver of Authorization Form, How to Complete the Sample HIPAA Research Authorization Form, Sample Research Authorization form, Research Sponsor Contract Privacy Provision

VII. REFERENCES

Standards for Privacy of Individually Identifiable Health Information, 45 CFR §164.501, §164.508, §164.512(i), §164.532(c), NY Civil Rights Law §79-1, NY Mental Hygiene Law §33.13, NY Mental Hygiene Law §33.16, NY Public Health Law §2782(1)

Revision	Required	Responsible Staff Name and Title
Yes	No	Adeola O. Dabiri, Director of Regulatory Affairs
Yes	No	



RESEARCHER CERTIFICATION FOR REVIEWS PREPARATORY TO RESEARCH

This form must be completed by any researcher seeking access to protected health information in preparation for research. Researcher Name: First MI Last **INFORMATION REQUESTED** Please describe in the space below the protected health information you would like to review. I seek access to the above protected health information solely to: Prepare a research protocol Other purpose preparatory to research; specify SPECIFIC REPRESENTATIONS I will not remove any of the above information from SUNY Downstate's premises during the course of my review. I affirm that access to the above protected health information is necessary for my review preparatory to research. I understand that I may not record any protected health information in a way that may directly or indirectly be used to identify particular individuals in accordance with the policy on De-Identification of Information. I understand that I may not continue to use and disclose the protected health information described above without further permission once the Principal Investigator has determined to go forward with the study. By signing below, I represent that all of the above statements are true. Print Name of Researcher Signature of Researcher Date



RESEARCHER CERTIFICATION FOR PHI OF DECEDENTS

This form must be completed by any researcher seeking access to a decedent's protected health information for research on that decedent. Researcher Name: Last First MI **INFORMATION REQUESTED** Please describe in the space below the protected health information [including the name of the decedent(s)] you would like to review. SPECIFIC REPRESENTATIONS I seek access to the above protected health information solely for research on the protected health information of the decedent(s) named above. I understand that I may not request a decedent's medical history to obtain information about another living person such as a decedent's living relative. I affirm that access to the above protected health information is necessary for my research purposes. I agree to provide, at the Research Foundation's request, documentation of the death of the decedent(s) named above. By signing below, I represent that all of the above statements are true. Print Name of Researcher Signature of Researcher Date



HIPAA WAIVER OF AUTHORIZATION FORM

Principal Investigator:		Study Title:	
PΑ	RT A- To be completed by the Principal Inv	estigator	
1.	Provide a brief description of the individual's i requesting access to or use of without patient	identifiable health information (IIHI) for which you are nt authorization:	
2.		improper use or disclosure. This plan must be adequate red and who will have access to it (ie., Sponsor, OHRP, ch team as listed on IRB application):	
3.		at the earliest opportunity consistent with the conduct of justification for retaining the identifiers or retention is	
4.	Provide an explanation as to why the researc	h cannot practicably be carried out without the waiver:	
5.	5. Provide an explanation as to why the research cannot practicably be conducted without acces and use of IIHI:		
	r signature below assures that the IIHI will no cept as required by law or for other research sp	ot be reused or disclosed to any other person or entity pecifically approved by the IRB.	
Pri	ncipal Investigator Signature	Date	
PA	RT B- To be completed by the IRB		
	Approved Denied; Reason for Denied	enial:	
IRI	3 Chair Signature/ Designee Signature	Date of Review	



HOW TO COMPLETE THE SAMPLE HIPAA RESEARCH AUTHORIZATION FORM

The Research Authorization form will need to be carefully prepared by the Principal Investigator to ensure that the form covers the necessary uses and disclosures of protected health information (PHI). The person(s) preparing the Research Authorization form for the individual to sign must follow these instructions.

IT IS THE RESPONSIBILITY OF THE RESEARCH STAFF TO ENSURE THAT SUNY DOWNSTATE HAS ON FILE A WRITTEN ACKNOWLEDGMENT OF RECEIPT BY THE SUBJECT OF ITS NOTICE OF PRIVACY PRACTICES. IF THE SUBJECT HAS NOT ALREADY DONE SO, HE OR SHE MUST SIGN SUCH AN ACKNOWLEDGEMENT BEFORE PARTICIPATING IN THE STUDY.

- 1. "Who will disclose, receive and/or use the information?" Please list every person, class of persons or organization (including government agencies, companies, etc.) who might disclose, receive and/or use the information to which the form applies. Check the boxes on the form, as appropriate. Please note, however, that the persons and organizations listed beside the boxes are not intended to be all-inclusive. If a person or organization is not included on the research authorization form, that person or organization may not receive protected health information held by SUNY Downstate, create or use protected health information on the SUNY Downstate's premises for research purposes or disclose the protected health information to any other party.
- 2. "What information will be used or disclosed?" Describe the protected health information in a way that allows both the prospective subject and any person or organization that must disclose information pursuant to this authorization to understand what records may be used or disclosed. For example, acceptable descriptions would be "laboratory results from July 2002," "all laboratory results" or "results of MRI performed in July 2002."

Note that for any disclosure of HIV-related information for research purposes, the appropriate box must be checked and a description of the specific HIV-related information must be included. Recipients are prohibited from re-disclosing the information without the subject's authorization, unless permitted under state or federal law.

3. "What is the expiration date or event for this Research Authorization form?"- The expiration date or event must related to the subject or the purpose of the use or disclosure. The statement "End of research study", "None" or similar language is sufficient if the authorization isfor a use or disclosure of PHI for research, including for the creation and maintenance of a research database or research repository.



SAMPLE RESEARCH AUTHORIZATION

We understand that information about you and your health is personal and we are committed to protecting the privacy of that information. Because of this commitment, we must obtain your written authorization before we may use or disclose your protected health information for the research purposes described below. This form provides that authorization and helps us make sure that you are properly informed of how this information will be used or disclosed. Please read the information below carefully before signing this form. A representative of SUNY Downstate is available to answer any questions regarding this authorization.

۸ ddrccc.	me:	MR#:		
Address:				
DOB:	Telephone#:	(Day)	(Eve)	
of persons only use a his/her per Eve sta Eve and Info The Prival Stu Me	Il disclose, receive and/or use the information and/or organization(s) may disclose, use and disclose the information to the other participation and representative or as required by law. Bery research site for this study, including Stand medical staff ery health care provider who provides service alboratories, other individuals and observation in connection with this study in access following research sponsors: Be United States Food and Drug Administration and staff of SUNY Downstate wacy Board incipal Investigator: Be dy Coordinator: Be members of the Research Team: Be members of the Research Foundation Be mitract Research Organization Name: Be mitract Research Organization Name:	and receive the information ties on this list, to the result of the second ties on this list, to the result of the second ties to you in connection we remain the study or dance with the study or second ties affiliated Institutional Figure 1.	on, but they may search subject or h sites' research sith this study ze your health protocol	

2. What information will be used or disclosed? The appropriate boxes should be checked
below and the descriptions should be in enough detail so that you (or any organization that mus disclose information pursuant to this authorization) can understand what information may be used or disclosed.
☐ The entire research record and any medical records held by SUNY Downstate may be used and disclosed.
□ HIV-related information, which includes any information indicating that you have had ar HIV-related test, or have HIV infection, HIV-related illness or AIDS or any information which could indicate that you have been potentially exposed to HIV.
☐ The following information:
3. What is the expiration date or event for this Research Authorization form?

SPECIFIC UNDERSTANDINGS

By signing this research authorization form, you authorize the use and/or disclosure of your protected health information described above. The purpose for the uses and disclosures you are authorizing is to conduct the research project explained to you during the informed consent process and to ensure that the information relating to that research is available to all parties who may need it for research purposes. Your information may also be used as necessary for your research-related treatment, to collect payment for your research-related treatment (when applicable) and to run the business operations of SUNY Downstate.

This information may be re-disclosed if the recipient(s) described on this form is not required by law to protect the privacy of the information.

You have a right to refuse to sign this authorization. While your health care outside the study, the payment for your health care and your health care benefits will not be affected if you do not sign this form, you will not be able to participate in the research described in this authorization and will not receive treatment as a study participant if you do not sign this form.

If you sign this authorization, you will have the right to revoke it at any time, except to the extent that the hospital has already taken action based upon your authorization or needs the information to complete analysis and reports of data for this research. To revoke this authorization, please write to:

SUNY Downstate Medical Center Research Foundation 450 Clarkson Ave. Brooklyn, NY 11203

You have a right to see and copy the information described on this authorization form in accordance with our policies. You also have a right to receive a copy of this form after you have signed it.

Notice Concerning HIV-Related Information

If you are authorizing the release of HIV-related information, you should be aware that the recipient(s) is prohibited from re-disclosing any HIV-related information without your authorization unless permitted to do so under federal or state law. You also have a right to request a list of people who may receive or use your HIV-related information without authorization. If you experience discrimination because of the release or disclosure of HIV-related information, you may contact the New York State Division of Human Rights at (212) 870-8624 or the New York City Commission of Human Rights at (212) 566-5493. These agencies are responsible for protecting your rights.

By signing below, I acknowledge that I have read and accept all of the above.				
Print Name of Patient	Signature of Patient			
Date				
If you are signing as a personal representative of the par	tient, read and sign below:			
I,, hereby	certify and attest that I am the duly authorized personal $% \left(1\right) =\left(1\right) \left(1\right) \left($			
representative of	and that I have the lawful provisions set forth in this			
authorization and agree to the use and/or disclosure of t	the patient's information for the purposes set forth herein.			
Print Name	Signature			
Date				
	AL REPRESENTATIVE MUST BE PROVIDED I AFTER IT HAS BEEN SIGNED.			
FOR SUNY DOWNSTATE USE ONLY:				
	certify that this Research Authorization complies with SUNY arch Purposes and with the Health Insurance Portability and s.			
Print Name of Research Foundation Administration	Print Name of Principal Investigator			
Signature of Basearch Foundation Administration	Data			



RESEARCH SPONSOR CONTRACT PRIVACY PROVISION

The following language may be used in a contract with a research sponsor to protect the confidentiality of individually identifiable health information provided to the sponsor in connection with the research. If the sponsor is not a covered entity under HIPAA, there may be no other way to restrict the sponsor's use or disclosure of the information. In some cases, the sponsor may want to be able to use and disclose such information and may object to any limiting language. Whatever language is inserted must be consistent with the description of the sponsor's uses and disclosures set forth in the research authorization signed by the subject. This language has been incorporated into a standard provision addressing the confidentiality of proprietary information in order to demonstrate how providers may choose to integrate this language into their existing research sponsor contracts or new contracts proposed by research sponsors.

Confidential Information.

- In the performance of this Agreement, each party is likely to have contact with 1.1 information of substantial value to the other, including, without limitation, information relating to identified patients and/or study subjects or to patients and/or study subjects whose identities may be ascertained by the exercise of reasonable effort through investigation or through use of other public or private databases; scientific techniques, designs, drawings, processes, inventions, developments, equipment, prototypes, sales and customer information; and business and financial information, relating to the business, products, practices or techniques (all of the foregoing hereinafter referred to as "Confidential Information"). Each party agrees, at all times, to regard and preserve as confidential such Confidential Information, and to refrain from publishing or disclosing any part of such Confidential Information or from using it, except as expressly otherwise provided pursuant to the terms and conditions of this Agreement. Sponsor agrees that it will keep and maintain in its custody and subject to its control any Hospital Confidential Information that it receives during the term of this Agreement, and agrees to return or surrender to Hospital, as the case may be, any Hospital Confidential Information upon termination of this Agreement.
- 1.2 Information received from either party to this Agreement shall not be deemed Confidential Information, and the receiving party shall have no obligation with respect to such information if: (i) such information, as of the effective date of this Agreement, is part of the public domain or becomes part of the public domain through no fault of the receiving party; (ii) such information was in possession of the receiving party on the effective date of this Agreement, as evidenced by prior written records kept in the ordinary course of the receiving party's business, and the information had not been wrongfully acquired, directly or indirectly, from the other party; (iii) such information is subsequently disclosed to the receiving party by a third party not in violation of any right of, or obligation to, the other party to this Agreement; (iv) such information is developed independently and without reference to the Confidential Information; or (v) such information is required by Hospital for medical treatment or patient counseling of study subjects.

- 1.3 In the event that either party receives a request to produce Confidential Information pursuant to an order of a court of competent jurisdiction or a facially valid administrative, Congressional, state or local legislative or other subpoena, or believes that such party is otherwise required by law to disclose Confidential Information, then the party from whom disclosure is sought shall promptly notify the other party to this Agreement prior to making such disclosure, and shall afford such party the opportunity to challenge or otherwise lawfully seek limits upon such disclosure of Confidential Information. The parties recognize a common goal of securing all individually identifiable health information and according that information the highest possible degree of confidentiality and protection from disclosure and will use their best efforts in that regard.
- 1.4 The parties recognize a common goal of securing the integrity of all individually identifiable health information and according that information the highest possible degree of confidentiality and protection from disclosure. The parties will use their best efforts in that regard. Notwithstanding the foregoing provisions of this Section 1, or anything else in this Agreement to the contrary:
- 1.4.1 all individually identifiable health information (including information relating to patients and/or study subjects whose identities may be ascertained by the exercise of reasonable effort through investigation or through use of other public or private databases) shall be treated as confidential by the parties in accordance with all applicable federal, state and local laws, rules and regulations governing the confidentiality and privacy of individually identifiable health information, including, but without limitation, to the extent that each party is subject to it, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and any regulations and official guidance promulgated thereunder; and the parties agree to take such additional steps and/or to negotiate such amendments to this Agreement as may be required to ensure that the parties are and remain in compliance with the HIPAA regulations and official guidance; and
- 1.4.2. the Sponsor, even if not a covered entity under HIPAA, recognizes that pursuant to this Agreement, Sponsor has the responsibility to protect all individually identifiable patient information consistent with the protections afforded to that information as Confidential Information set forth above; and only to use and disclose such information as necessary to discuss and analyze the results of the study, to ensure research integrity, to communicate with the Food and Drug Administration and other regulatory authorities, and otherwise as required by law or as permitted by authorizations or consents signed by study subjects or waiver of authorization granted by an IRB overseeing the study or that IRB's affiliated Privacy Board (the "Permitted Activities"); and to restrict the use and disclosure of any individually identifiable patient information gained through the Permitted Activities to its workforce, contractors, subcontractors, study collaborators and agents who must have access to that information in order directly to support or facilitate the Permitted Activities; and to notify its workforce members, contractors, subcontractors, and agents of the requirements regarding protecting, using and disclosing such information in the fulfillment of their assigned duties, and to use any necessary means to bind those parties to these restrictions and requirements relating to individually identifiable patient information: and

1.4.3. the parties agree to cooperate with any reasonable requests from third party payors and/or government agencies with respect to the medical necessity of and reimbursement for medical services furnished to patients enrolled in the study, to the extent that those services are not reimbursed by Sponsor pursuant to this Agreement, and the parties shall cooperate with each other to narrow the scope of any such request from third party payors.

Please note that some sponsors may object to any mention that they are subject to HIPAA; in that case, it may be acceptable to eliminate references to HIPAA in this paragraph, instead retaining references to "all applicable federal and state local laws."